Law360, New York (September 16, 2011, 9:08 PM ET) -- Sun Pharmaceutical Industries Ltd. can't market its generic version of Sanofi-Aventis SA's colorectal cancer treatment Eloxatin until August 2012, based on the terms of a licensing agreement between the companies, a New Jersey federal judge said Thursday.
U.S. District Court Judge Joel A. Pisano reinstated his April 22, 2010, judgment entering a consent decree that resolved Sanofi's patent infringement suit against Sun. The decree includes licensing language stating that if other generics makers were enjoined from selling their version of Eloxatin at-risk, Sun would be enjoined...
Sun Can't Sell Generic Eloxatin Until 2012: Judge
To view the full article, take a free trial now.
